Patients with acute myocardial infarction demonstrate a greater tendency for in vitro platelet release in the acute phase, which normalizes by 6 months.
Answers are grounded in this paper and cite their sources.
No clinical study data available; leaves open questions on post-MI platelet activity and its clinical relevance.
Summary In vivo platelet activity was studied in 58 patients with AMI on admittance to the Coronary Care Unit, in 48 of these patients after 1 week, in 30 after 1 month and in 24 patients after 6 months. Patients were carefully selected and excluded if they had associated diseases known to increase platelet activity. In vivo activation was studied by evaluating the plasma concentration of beta-thromboglobulin (β-TG) and platelet factor 4 (PF4) in the same blood sample. On admittance (x = 58.5) and on day 7 (x = 52.9) β-TG values were significantly higher than those obtained in the control group (x = 29). β-TG values were moderately elevated after 1 month (x = 37.7) and then returned to values similar to those of the control group after 6 months (x = 27.9). The simultaneous assessment of PF4 shows a β-TG/PF4 ratio indicative for in vitro release (≤2.5) in many patients on days 1 and 7. Moreover, the β-TG/PF4 ratio in patients with AMI tends towards 2 when β-TG values are high. These results may indicate a greater tendency to an in vitro platelet release in the acute phase of AMI.
No takes yet. Share an insight, caveat, or question.
Pengo et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: